{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:21Z","timestamp":1792786101893,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSL Vifor and Roche"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA. The 2024 KDIGO clinical practice guidelines for AAV now incorporate avacopan as an alternative to GC for remission induction. Phase 3 trials in EGPA have demonstrated superiority of mepolizumab versus placebo (MIRRA, 2017) and non-inferiority of benralizumab versus mepolizumab (MANDARA, 2024) for sustaining remission. Real-world data, as presented in this session, are essential to understand the efficacy and safety of these new therapies in broader AAV patient populations.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae426","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:06:28Z","timestamp":1723057588000},"page":"i117-i119","source":"Crossref","is-referenced-by-count":3,"title":["Highlights from the breakout session: optimising new treatments"],"prefix":"10.1093","volume":"64","author":[{"given":"Lucy","family":"Francis","sequence":"first","affiliation":[{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]},{"name":"Department of Medicine, University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Dhutia","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Imperial College Healthcare NHS Trust , London,","place":["UK"]},{"name":"Department of Immunology and Inflammation, Imperial College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Pusey","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Imperial College Healthcare NHS Trust , London,","place":["UK"]},{"name":"Department of Immunology and Inflammation, Imperial College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B","family":"Jones","sequence":"additional","affiliation":[{"name":"Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge,","place":["UK"]},{"name":"Department of Medicine, University of Cambridge , Cambridge,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025031209170047500_keae426-B1","doi-asserted-by":"publisher","author":"21st International Vasculitis Workshop. 21st International Vasculitis Workshop. Abstracts Book. Zenodo; 2024.","DOI":"10.5281\/zenodo.11068008"},{"key":"2025031209170047500_keae426-B2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"key":"2025031209170047500_keae426-B3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025031209170047500_keae426-B4","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated Vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025031209170047500_keae426-B5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025031209170047500_keae426-B6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ndt\/gfac330","article-title":"Avacopan for ANCA-associated vasculitis\u2014information for prescribers","volume":"38","author":"McGovern","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025031209170047500_keae426-B7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of Avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025031209170047500_keae426-B8","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025031209170047500_keae426-B9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ndt\/gfy075","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"33","author":"McAdoo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025031209170047500_keae426-B10","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025031209170047500_keae426-B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025031209170047500_keae426-B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025031209170047500_keae426-B13","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2025031209170047500_keae426-B14","doi-asserted-by":"crossref","first-page":"00509","DOI":"10.1183\/23120541.00509-2023","article-title":"Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics","volume":"10","author":"Jayne","year":"2024","journal-title":"ERJ Open Res"},{"key":"2025031209170047500_keae426-B15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"2025031209170047500_keae426-B16","doi-asserted-by":"crossref","first-page":"1145257","DOI":"10.3389\/fmed.2023.1145257","article-title":"Eosinophilic granulomatosis with polyangiitis\u2014advances in pathogenesis, diagnosis, and treatment","volume":"10","author":"Fijolek","year":"2023","journal-title":"Front Med (Lausanne)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i117\/62374906\/keae426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i117\/62374906\/keae426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:17:27Z","timestamp":1741756647000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_1\/i117\/8069398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":16,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae426","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3,1]]}}}